Klemens Budde

Klemens Budde's AcademicInfluence.com Rankings

Klemens Budde

Computer Science

#6885

World Rank

#7252

Historical Rank

Machine Learning

#2378

World Rank

#2407

Historical Rank

Artificial Intelligence

#2661

World Rank

#2702

Historical Rank

Database

#3966

World Rank

#4125

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Klemens Budde Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Klemens Budde's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial (2013) (687)
Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus (2007) (587)
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. (2005) (418)
Proceedings From an International Consensus Meeting on Posttransplantation Diabetes Mellitus: Recommendations and Future Directions (2014) (360)
Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts (2009) (343)
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial (2011) (334)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (2019) (306)
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. (2002) (282)
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report (2019) (274)
Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction (2004) (265)
Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial (2008) (260)
CC chemokine receptor 5 and renal-transplant survival (2001) (257)
Enteric‐Coated Mycophenolate Sodium can be Safely Administered in Maintenance Renal Transplant Patients: Results of a 1‐Year Study (2004) (253)
Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation (2005) (234)
Donor‐Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation (2012) (234)
Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients (2005) (220)
Biomarkers in acute kidney injury – pathophysiological basis and clinical performance (2017) (216)
Everolimus in patients with autosomal dominant polycystic kidney disease. (2010) (208)
Neutrophil gelatinase‐associated lipocalin: pathophysiology and clinical applications (2013) (202)
Interleukin 6 is an autocrine growth factor for mesangial cells. (1990) (201)
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) (2011) (189)
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. (2021) (189)
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. (2003) (178)
Diets and enteral supplements for improving outcomes in chronic kidney disease (2011) (176)
Pre‐Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation (2004) (161)
Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. (2003) (159)
Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients (1999) (156)
Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. (2016) (156)
FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1‐Year, Randomized Controlled Trial in Europe and Australasia (2006) (151)
The pharmacokinetics of pioglitazone in patients with impaired renal function. (2003) (147)
Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year (2012) (140)
Hyperforin content determines the magnitude of the St John's Wort–cyclosporine drug interaction (2004) (136)
Old‐for‐Old Kidney Allocation Allows Successful Expansion of the Donor and Recipient Pool (2003) (127)
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients (2008) (126)
Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. (2000) (125)
UGT1A9 −275T>A/−2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus‐Treated Kidney Transplant Patients (2009) (123)
Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. (2016) (122)
Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group (2019) (120)
Age-matching in renal transplantation. (2000) (119)
Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. (2012) (118)
Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study (2014) (117)
Motivations, Challenges, and Attitudes to Self-management in Kidney Transplant Recipients: A Systematic Review of Qualitative Studies. (2016) (115)
Five‐Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study (2015) (114)
Pharmacokinetic and Pharmacodynamic Comparison of Enteric‐Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients (2007) (114)
Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk (2010) (112)
Quality of Life of Living Kidney Donors in Germany: A Survey with the Validated Short Form-36 and Giessen Subjective Complaints List-24 Questionnaires (2004) (110)
Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients (2003) (105)
Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study (2017) (105)
Therapeutic Drug Monitoring of Everolimus: A Consensus Report (2016) (104)
Donor–Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor‐Specific HLA Antibodies Following Renal Transplantation (2017) (100)
Formation of extracellular matrix by cultured rat mesangial cells. (1989) (99)
The need for minimization strategies: current problems of immunosuppression (2015) (98)
Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. (2001) (95)
FTY720 (fingolimod) in renal transplantation (2006) (95)
Novel views on new-onset diabetes after transplantation: development, prevention and treatment. (2013) (94)
Review of the immunosuppressant enteric-coated mycophenolate sodium (2004) (93)
Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study (2018) (91)
Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism (2009) (90)
Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3‐Year Results From the Randomized ZEUS Study (2012) (90)
Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition. (2012) (86)
Testosterone Concentrations and Sirolimus in Male Renal Transplant Patients (2004) (86)
TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study (2018) (85)
Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. (1999) (85)
Calcium Channel Blockade and Preservation of Renal Graft Function in Cyclosporine-Treated Recipients: A Prospective Randomized Placebo-Controlled 2-Year Study (2004) (83)
Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients (2013) (83)
Long‐term risks of kidney living donation: review and position paper by the ERA‐EDTA DESCARTES working group (2017) (82)
Sotrastaurin, a Novel Small Molecule Inhibiting Protein‐Kinase C: Randomized Phase II Study in Renal Transplant Recipients (2011) (82)
Novel Once‐Daily Extended‐Release Tacrolimus (LCPT) Versus Twice‐Daily Tacrolimus in De Novo Kidney Transplants: One‐Year Results of Phase III, Double‐Blind, Randomized Trial (2014) (82)
Weight gain in long-term survivors of kidney or liver transplantation--another paradigm of sarcopenic obesity? (2012) (80)
Epidemiological Approach to Identifying Genetic Predispositions for Atypical Hemolytic Uremic Syndrome (2010) (80)
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation (2016) (80)
Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal‐Transplant Recipients (2010) (79)
MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. (2004) (78)
Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Maintenance Renal Transplant Recipients Receiving Tacrolimus: Clinical, Pharmacokinetic, and Pharmacodynamic Outcomes (2007) (78)
Three-Year Observational Follow-up of a Multicenter, Randomized Trial on Tacrolimus-Based Therapy with Withdrawal of Steroids or Mycophenolate Mofetil after Renal Transplant (2006) (77)
Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients (2007) (77)
A systematic approach to managing pregnant dialysis patients--the importance of an intensified haemodiafiltration protocol. (2005) (76)
Strategies to increase the donor pool and access to kidney transplantation: an international perspective (2014) (75)
Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(®)) in renal transplant recipients. (2012) (74)
De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. (1999) (74)
European Association of Urology Guidelines on Renal Transplantation: Update 2018. (2018) (74)
Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. (2006) (73)
Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial (2012) (73)
Pharmacodynamic Monitoring of Mycophenolate Mofetil (2000) (71)
Interleukin-6 expression after renal transplantation. (1997) (71)
TNF-α AND IL-1α INDUCE APOPTOSIS IN SUBCONFLUENT RAT MESANGIAL CELLS. EVIDENCE FOR THE INVOLVEMENT OF HYDROGEN PEROXIDE AND LIPID PEROXIDATION AS SECOND MESSENGERS (2000) (70)
Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. (2010) (69)
Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. (2008) (68)
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. (2020) (66)
MDR1 Haplotypes Do Not Affect the Steady‐State Pharmacokinetics of Cyclosporine in Renal Transplant Patients (2003) (66)
Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation: Report of the Standardized Outcomes in Nephrology—Kidney Transplantation Consensus Workshops (2017) (65)
Use of Neoral C2 monitoring: a European consensus (2005) (65)
The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. (1998) (65)
Effect of Pregnancy on Long‐Term Kidney Function in Renal Transplant Recipients Treated with Cyclosporine and with Azathioprine (2005) (65)
Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. (2011) (64)
Validation of Immunological Biomarkers for the Pharmacodynamic Monitoring of Immunosuppressive Drugs in Humans (2007) (64)
Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. (2016) (64)
Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients (2010) (63)
"Old-for-old" cadaveric renal transplantation: surgical findings, perioperative complications and outcome. (2003) (63)
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. (2020) (61)
Improved Assay for the Nonradioactive Determination of Inosine 5'-Monophosphate Dehydrogenase Activity in Peripheral Blood Mononuclear Cells (2009) (61)
Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. (2003) (61)
Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals (2017) (60)
A Cardiovascular Risk Calculator for Renal Transplant Recipients (2012) (59)
Improved diagnosis of early kidney allograft dysfunction by ultrasound with echo enhancer--a new method for the diagnosis of renal perfusion. (2006) (59)
Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. (2010) (58)
Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid (2010) (56)
The Severity of Acute Cellular Rejection Defined by Banff Classification Is Associated With Kidney Allograft Outcomes (2014) (53)
The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. (2004) (53)
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. (2021) (52)
Outcomes of transplanting deceased-donor kidneys between elderly donors and recipients. (2009) (52)
Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells. (2002) (52)
‘Suspended in a paradox’—patient attitudes to wait‐listing for kidney transplantation: systematic review and thematic synthesis of qualitative studies (2015) (51)
Population Pharmacokinetics of Mycophenolic Acid (2008) (50)
The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. (2004) (49)
Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction. (2017) (48)
Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations (2010) (48)
Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients (2015) (48)
Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. (2005) (48)
Treatment of PTLD with Rituximab and CHOP Reduces the Risk of Renal Graft Impairment after Reduction of Immunosuppression (2009) (48)
Experience with belatacept rescue therapy in kidney transplant recipients (2016) (47)
Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. (1999) (47)
Hypertension in patients after renal transplantation. (1997) (47)
Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. (2002) (47)
The 'blood group O problem' in kidney transplantation--time to change? (2010) (46)
Improved Left Ventricular Structure and Function After Successful Kidney Transplantation (2016) (45)
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial (2019) (45)
Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation (2018) (45)
The use of contrast-enhanced US in renal transplant: first results and potential clinical benefit (2005) (45)
Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. (2010) (45)
Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. (2005) (45)
AcylMPAG Plasma Concentrations and Mycophenolic Acid-Related Side Effects in Patients Undergoing Renal Transplantation Are Not Related to the UGT2B7-840G>A Gene Polymorphism (2008) (45)
Urinary miR‐155‐5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation (2017) (44)
Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients (2022) (44)
Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. (2004) (44)
A Randomized Trial Comparing Renal Function in Older Kidney Transplant Patients Following Delayed Versus Immediate Tacrolimus Administration (2009) (44)
Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results (2013) (43)
FTY720, a Novel Immunomodulator in de Novo Kidney Transplant Patients: Pharmacokinetics and Exposure‐Response Relationship (2005) (42)
Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1. (2015) (42)
Pharmacokinetics of Intravenous, Single‐Dose Tiotropium in Subjects with Different Degrees of Renal Impairment (2004) (41)
Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study (2018) (41)
The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. (2018) (41)
Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? (1999) (40)
FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. (2004) (40)
Review of bortezomib treatment of antibody-mediated rejection in renal transplantation. (2014) (40)
FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. (2004) (40)
Exploring the Complexity of Death-Censored Kidney Allograft Failure (2021) (40)
The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. (2016) (40)
Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. (2001) (40)
Negation Detection in Clinical Reports Written in German (2016) (40)
The Preferences and Perspectives of Nephrologists on Patients’ Access to Kidney Transplantation: A Systematic Review (2014) (39)
A randomized, phase 2 study of ASP0113, a DNA‐based vaccine, for the prevention of CMV in CMV‐seronegative kidney transplant recipients receiving a kidney from a CMV‐seropositive donor (2018) (39)
Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation (2017) (38)
Sotrastaurin in Calcineurin Inhibitor–Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients (2013) (37)
Conversion to sirolimus for chronic allograft dysfunction: long‐term results confirm predictive value of proteinuria (2007) (37)
Pharmacokinetic principles of immunosuppressive drugs. (2008) (37)
Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board* (2018) (37)
Pregnancy on Intensified Hemodialysis: Fetal Surveillance and Perinatal Outcome (2007) (36)
Volume matters: CT‐based renal cortex volume measurement in the evaluation of living kidney donors (2013) (36)
Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. (2015) (35)
Biomarkers of Over‐Immunosuppression (2011) (35)
Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects (2016) (35)
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor–Mediated Podocyte &bgr;3-integrin Activation (2015) (35)
Enteric-Coated Mycophenolate Sodium Provides Higher Mycophenolic Acid Predose Levels Compared With Mycophenolate Mofetil: Implications for Therapeutic Drug Monitoring (2007) (34)
Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation (2011) (34)
Age‐Related Penetrance of Hereditary Atypical Hemolytic Uremic Syndrome (2011) (34)
Assessment of the Kidney Donor Profile Index in a European cohort (2018) (33)
First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis (2019) (33)
Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study (2016) (33)
Arrival time parametric imaging: a new ultrasound technique for quantifying perfusion of kidney grafts. (2007) (33)
Need for optimized immunosuppression in elderly kidney transplant recipients. (2015) (33)
Effects of sotrastaurin, mycophenolic acid and everolimus on human B‐lymphocyte function and activation (2012) (33)
Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study. (2019) (32)
Pretransplant virtual PRA and long‐term outcomes of kidney transplant recipients (2015) (32)
Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients. (2001) (32)
An evaluation of sirolimus in renal transplantation (2012) (32)
Interleukin-8 expression in patients after renal transplantation. (1997) (32)
Identification and Therapeutic Management of Highly Sensitized Patients Undergoing Renal Transplantation (2012) (31)
Reports of Large Immunosuppression Trials in Kidney Transplantation: Room for Improvement (2004) (31)
Gadolinium-enhanced three-dimensional magnetic resonance angiography versus conventional digital subtraction angiography: which modality is superior in evaluating living kidney donors? (2003) (31)
Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial (2017) (31)
Laparoscopic versus open donor nephrectomy in Germany: impact on donor health-related quality of life and willingness to donate. (2005) (31)
Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis. (2005) (31)
TNF-alpha and IL-1alpha induce apoptosis in subconfluent rat mesangial cells. Evidence for the involvement of hydrogen peroxide and lipid peroxidation as second messengers. (2000) (31)
Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation (2016) (30)
Inosine 5'-monophosphate dehydrogenase activity as a biomarker in the field of transplantation. (2012) (30)
Banff survey on antibody‐mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications (2018) (30)
Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. (2016) (30)
Transmission of breast cancer by a single multiorgan donor to 4 transplant recipients (2018) (30)
Identification of T Cell–Mediated Vascular Rejection After Kidney Transplantation by the Combined Measurement of 5 Specific MicroRNAs in Blood (2016) (29)
Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). (2006) (29)
Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation (2017) (29)
The Clinical Data Intelligence Project (2016) (29)
Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe (2018) (29)
Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms (2014) (28)
The quality of life in end stage renal disease care (1998) (28)
Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients (2022) (28)
Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium (2009) (28)
Factors associated with kidney graft survival in pure antibody‐mediated rejection at the time of indication biopsy: Importance of parenchymal injury but not disease activity (2020) (27)
European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care (2017) (27)
Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients (2011) (27)
Sirolimus and lymphocele formation after kidney transplantation: an immunosuppressive medication as co-factor for a surgical problem? (2003) (27)
Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation. (2009) (27)
Clinical Outcome Prediction from Admission Notes using Self-Supervised Knowledge Integration (2021) (26)
Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2 (2018) (26)
Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients (2017) (26)
Pregnancy following kidney transplantation - impact on mother and graft function and focus on childrens’ longitudinal development (2019) (26)
Tabebuia avellanedae extracts inhibit IL-2-independent T-lymphocyte activation and proliferation. (2008) (25)
LCPT once‐daily extended‐release tacrolimus tablets versus twice‐daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups (2016) (25)
Immunosuppression in renal transplantation: some aspects for the modern era. (2008) (25)
CytoSorb Rescue for COVID-19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open-Label, Randomized Controlled Pilot Study* (2022) (24)
Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. (2003) (24)
Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. (2007) (24)
Rat mesangial cells produce granulocyte-macrophage colony-stimulating factor. (1989) (24)
Adjustment of target weight based on absolute blood volume reduces the frequency of intradialytic morbid events (2018) (24)
Prognostic value of the Banff classification (2000) (24)
Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic Review (2018) (24)
Pre-operative assessment of living renal transplant donors with state-of-the-art imaging modalities: computed tomography angiography versus magnetic resonance angiography in 118 patients (2013) (24)
Limitations of C2 monitoring in renal transplant recipients. (2005) (24)
Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4‐year results from the randomized EXIST‐1 and EXIST‐2 studies (2018) (23)
Enteric-coated mycophenolate sodium (2010) (23)
FTY720: early clinical experience. (2004) (23)
Genetic polymorphisms in IL‐2, IL‐10, TGF‐β1, and IL‐2RB and acute rejection in renal transplant patients (2014) (23)
Risk Evaluation and Outcome of Pneumocystis jirovecii Pneumonia in Kidney Transplant Patients. (2016) (23)
'I feel stronger and younger all the time'-perspectives of elderly kidney transplant recipients: thematic synthesis of qualitative research. (2016) (22)
Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. (2016) (22)
Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy. (2016) (22)
Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year. (1996) (22)
Current perspectives on FTY720 (2007) (21)
A fine-grained corpus annotation schema of German nephrology records (2016) (21)
Acute cellular rejection with isolated v‐lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations (2014) (21)
Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. (2004) (21)
S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. (2007) (21)
Immunosuppression in the elderly renal allograft recipient: a systematic review. (2016) (21)
Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid After Enteric‐Coated Mycophenolate Versus Mycophenolate Mofetil in Patients With Progressive IgA Nephritis (2007) (21)
Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation. (2018) (20)
Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex (2018) (20)
Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19 (2021) (20)
The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation (2021) (20)
Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid (2012) (19)
FTY720 MEDIATES APOPTOSIS-INDEPENDENT LYMPHOPENIA IN HUMAN RENAL ALLOGRAFT RECIPIENTS: DIFFERENT EFFECTS ON CD62L+ AND CCR5+ T LYMPHOCYTES (2004) (19)
Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (2018) (19)
Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. (2012) (19)
Evaluation of adherence and tolerability of prolonged‐release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study (2018) (19)
Conversion from Calcineurin Inhibitor– to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial (2021) (19)
Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine. (2006) (18)
Pharmacokinetics of Sotrastaurin Combined With Tacrolimus or Mycophenolic Acid in De Novo Kidney Transplant Recipients (2011) (18)
Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study. (2005) (18)
Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching? (2016) (18)
Increased frequency of lymphoceles under treatment with sirolimus following renal transplantation: a single center experience. (2002) (18)
How Delayed Graft Function Impacts Exposure to Mycophenolic Acid in Patients After Renal Transplantation (2011) (18)
Lectin-like oxidized low-density lipoprotein (LDL) receptor (LOX-1)-mediated pathway and vascular oxidative injury in older-age rat renal transplants. (2005) (18)
Any Progress in the Treatment of Antibody-Mediated Rejection? (2018) (18)
Online haemodiafiltration: definition, dose quantification and safety revisited (2013) (18)
Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients. (2002) (18)
Comparison of first and second kidney transplants from the same deceased donor. (2010) (17)
Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients. (1998) (17)
Effects of the new immunosuppressive agent AEB071 on human immune cells. (2010) (17)
eHealth in transplantation (2020) (17)
Validation of the Living Kidney Donor Profile Index in a European cohort and comparison of long-term outcomes with US results. (2019) (17)
Clinical Utility of a New Enzymatic Assay for Determination of Mycophenolic Acid in Comparison With an Optimized LC-MS/MS Method (2009) (17)
Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. (2007) (17)
The inferior impact of antibody‐mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy (2016) (17)
20-year experience with elderly donors in living renal transplantation. (2003) (17)
Non‐invasive imaging of living kidney donors: intraindividual comparison of multislice computed tomography angiography with magnetic resonance angiography (2012) (17)
TBC1D8B Mutations Implicate RAB11-Dependent Vesicular Trafficking in the Pathogenesis of Nephrotic Syndrome. (2019) (17)
Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients. (2004) (17)
Free microRNA levels in plasma distinguish T-cell mediated rejection from stable graft function after kidney transplantation. (2016) (17)
Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. (2011) (17)
The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. (2009) (17)
Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial (2015) (17)
The influence of age on outcome after renal transplantation. (1997) (17)
Attitude to nephrolithiasis in the potential living kidney donor: a survey of the German kidney transplant centers and review of the literature (2008) (16)
No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. (2015) (16)
MicroRNA regulation in blood cells of renal transplanted patients with interstitial fibrosis/tubular atrophy and antibody-mediated rejection (2018) (16)
Volume stress-induced peritoneal endothelin-1 release in continuous ambulatory peritoneal dialysis. (1999) (16)
Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation. (2000) (16)
FTV 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis‐independent mechanism (2000) (16)
TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients. (2021) (16)
Successful pregnancies in dialysis patients including those suffering from cystinosis and familial Mediterranean fever. (2006) (15)
Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients. (2005) (15)
Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic Factors. (2017) (15)
Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis (1998) (15)
Pre-existing malignancies in renal transplant candidates-time to reconsider waiting times. (2019) (15)
Research Paper: Recognition of Critical Situations from Time Series of Laboratory Results by Case-Based Reasoning (2002) (15)
Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. (2014) (14)
Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. (2020) (14)
Effectiveness and Harms of Using Kidneys with Small Renal Tumors from Deceased or Living Donors as a Source of Renal Transplantation: A Systematic Review. (2018) (14)
The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients. (2007) (14)
Successful living related kidney transplantation despite renal angiomyolipoma in situ. (1999) (14)
Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. (1996) (14)
Analysis of the Effects of Day-Time vs. Night-Time Surgery on Renal Transplant Patient Outcomes (2019) (14)
Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year. (1996) (13)
Glomerular epithelial cell products stimulate mesangial cell proliferation in culture. (1997) (13)
Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis. (2010) (13)
Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials (2018) (13)
Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center (2020) (13)
Treatment of Acute Antibody-Mediated Renal Allograft Rejection With Cyclophosphamide (2017) (13)
Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection (2016) (13)
Practice Variations in the Evaluation of Adult Candidates for Cadaveric Kidney Transplantation: A Survey of the European Transplant Centers. Transplantation 2000; 70: 1492. (2000) (13)
Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials (2007) (13)
Standard work-up of the low-risk kidney transplant candidate: a European expert survey of the ERA-EDTA Developing Education Science and Care for Renal Transplantation in European States Working Group. (2019) (13)
Transplantation: Sirolimus for secondary SCC prevention in renal transplantation (2012) (12)
Influence of Everolimus on Steady‐State Pharmacokinetics of Cyclosporine in Maintenance Renal Transplant Patients (2005) (12)
Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial (2018) (12)
Immunosuppression and Results in Renal Transplantation (2016) (12)
Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database (2014) (12)
FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism (2000) (12)
Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study (2014) (12)
RENAL FUNCTION, EFFICACY AND SAFETY OF EVEROLIMUS (RAD) / ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) THERAPY AFTER CALCINEURIN INHIBITOR (CNI) WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: FINAL OUTCOMES OF THE ZEUS STUDY: 264 (2008) (12)
Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments (2007) (12)
Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation (2017) (12)
Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients. (2001) (12)
The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open‐label comparative study (2014) (12)
Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC) (2017) (12)
HUMAN SAFETY AND PHARMACOLOGY OF FTY 720 (1999) (11)
Reporting of Rejection after Renal Transplantation in Large Immunosuppressive Trials: Biopsy-Proven, Clinical, Presumed, or Treated Rejection? (2006) (11)
Combined standard and novel immunosuppressive substances affect B-lymphocyte function. (2013) (11)
Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae-Related Urinary Tract Infection in Kidney Transplant Recipients: Risk Factors, Treatment, and Long-Term Outcome. (2017) (11)
Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients (2011) (11)
Five‐year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low‐exposure cyclosporine versus standard therapy (2018) (11)
Clinical outcome of norovirus infection in renal transplant patients (2016) (11)
Frequency and long‐term outcomes of post‐transplant hypophosphatemia after kidney transplantation (2013) (11)
High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation (2018) (11)
Differing proteinuria control with cyclosporin and tacrolimus (1997) (11)
Belatacept utilization recommendations: an expert position (2013) (11)
Bioavailability and costs of once‐daily and twice‐daily tacrolimus formulations in de novo kidney transplantation (2018) (11)
Relevance and meaning of prostate cancer in kidney transplantation. (2002) (11)
Enteric-Coated Mycophenolate Sodium A Review of its Use in the Prevention of Renal Transplant Rejection (2008) (11)
No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. (2004) (11)
Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series (2021) (11)
[A new method for standardized diagnosis following renal transplantation. Ultrasound with contrast enhancement]. (2006) (11)
Mycophenolate mofetil maintenance therapy in renal transplant patients: long‐term results of the TranCept STAY study (2012) (10)
Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up. (2002) (10)
Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial (2017) (10)
Accurate prediction of kidney allograft outcome based on creatinine course in the first 6 months posttransplant. (2005) (10)
Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. (2008) (10)
Detecting Named Entities and Relations in German Clinical Reports (2017) (10)
Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. (2010) (10)
A novel tool for the identification of correlations in medical data by faceted search (2017) (10)
Impact of Pre-existing Comorbidities on Long-term Outcomes in Kidney Transplant Recipients. (2018) (10)
A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation (2018) (10)
Undoubtedly, kidney transplant recipients have a higher mortality due to COVID‐19 disease compared to the general population (2021) (10)
Long-Term Outcomes of Kidney Transplant Recipients With Primary Idiopathic Focal Segmental Glomerulosclerosis. (2017) (10)
Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine. (2003) (10)
Laparoscopic donor nephrectomy in Germany. (2002) (10)
Impact of PGE1 on cyclosporine A induced up-regulation of TGF-beta1, its receptors, and related matrix production in cultured mesangial cells. (2003) (10)
Novel Mediators of FTY720 in Human Lymphocytes (2005) (10)
Effect of mycophenolate mofetil monotherapy on T-cell functions and inosine monophosphate dehydrogenase activity in patients undergoing a kidney transplantation. (2006) (10)
Advances in pharmacotherapy to treat kidney transplant rejection (2015) (10)
Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease. (1998) (10)
PHARMACOKINETIC AND PHARMACODYNAMIC COMPARISON OF MYCOPHENOLATE MOFETIL (MMF) AND ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN MAINTENANCE RENAL TRANSPLANT PATIENTS WITH TACROLIMUS AS BASIC IMMUNOSUPPRESSION (2004) (10)
Outcome of expanded criteria donor kidneys that were transplanted at other Eurotransplant centers after being rejected by our institution (2013) (10)
Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy. (2002) (10)
Treatment with QPI-1002, a Short Interfering (SI) RNA for the Prophylaxis of Delayed Graft Function.: Abstract# 2967 (2014) (9)
Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation (2016) (9)
Renal Allograft Loss Caused by Cardiorenal Syndrome: Frequency and Diagnosis (2015) (9)
Accumulation of elderly ESRD patients with blood group O on the waiting list (2011) (9)
Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients. (2007) (9)
The immunosuppressive potential of misoprostol--efficacy and variability. (2003) (9)
The Relationship of the Severity and Category of Acute Rejection With Intimal Arteritis Defined in Banff Classification to Clinical Outcomes (2015) (9)
A Web-Based Electronic Patient Record System as a Means for Collection of Clinical Data (2000) (9)
Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study (2014) (9)
The regulation of interferon type I pathway‐related genes RSAD2 and ETV7 specifically indicates antibody‐mediated rejection after kidney transplantation (2018) (9)
FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients. (2002) (9)
Target enzyme activity as a biomarker for immunosuppression. (2010) (9)
Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. (2016) (9)
Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step (2017) (9)
Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation (2016) (8)
Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA) (2021) (8)
Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease. (2015) (8)
Treating type 2 diabetes in renal insufficiency: the role of pioglitazone. (2003) (8)
Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis. (1998) (8)
Immunohistochemical double-staining of renal allograft tissue: critical assessment of three different protocols (2002) (8)
Proposal for Guidelines for Publication of Randomized Trials in the American Journal of Transplantation (2005) (8)
Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept (2020) (8)
A 2020 Banff Antibody‐mediatedInjury Working Group examination of international practices for diagnosing antibody‐mediated rejection in kidney transplantation – a cohort study (2021) (8)
New perspectives of immunosuppression. (2013) (8)
HUMAN PHARMACOKINETICS OF FTY 720 (1999) (8)
Impaired antigen-specific memory B cell and plasma cell responses including lack of specific IgG upon SARS-CoV-2 BNT162b2 vaccination among Kidney Transplant and Dialysis patients (2021) (8)
Pharmacodynamic monitoring of mycophenolate mofetil in renal allograft recipients. (2001) (8)
How to Use mTOR Inhibitors? The Search Goes On (2011) (8)
Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients. (2020) (8)
Early Postoperative Basal Insulin Therapy versus Standard of Care for the Prevention of Diabetes Mellitus after Kidney Transplantation: A Multicenter Randomized Trial (2021) (8)
Treatment With Sirolimus Is Associated With Less Weight Gain After Kidney Transplantation (2013) (8)
[Contraindications to living donor kidney transplantation]. (2005) (7)
A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. (2013) (7)
Eine neue Methode zur standardisierten Diagnostik nach Nierentransplantation (2005) (7)
Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism (2021) (7)
De-novo malignancies after kidney transplantation: A long-term observational study (2020) (7)
Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany. (2017) (7)
Donor Genotype and Intragraft Expression of CYP3A5 Reflect the Response to Steroid Treatment During Acute Renal Allograft Rejection (2014) (7)
Native Nephrectomy before and after Renal Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2019) (7)
Predictors of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Patients: Baseline Characteristics, Immunosuppression, and the Role of IMPDH Monitoring (2022) (7)
Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Results from EXIST-2. (2012) (7)
Pharmacodynamic monitoring of lymphocyte proliferation and TGF-beta 1 expression at cyclosporine a (CyA) trough levels (C(0)) and 2 hours after intake (C(2)) of CyA in human renal allograft recipients. (2001) (7)
Autoantibodies from Patients with Scleroderma Renal Crisis Promote PAR-1 Receptor Activation and IL-6 Production in Endothelial Cells (2021) (7)
Pathologic characteristics of early or late acute cellular rejection and outcome after kidney transplant. (2014) (7)
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials (2022) (7)
Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in de Novo Renal Transplant Patients: 4 Years Follow-Up of the ZEUS Trial: 1671 (2012) (7)
Laparoscopic kidney harvesting for living donor kidney transplantation--one year follow-up of the initial 15 patients. (2001) (6)
IMPROVED RENAL FUNCTION OF AN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM REGIMEN AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: 2 YEARS FOLLOW-UP OF THE ZEUS TRIAL: 1757 (2010) (6)
Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial (2022) (6)
Midterm echocardiographic follow-up of cardiac function after living kidney donation. (2015) (6)
SUCCESSFUL STEROID WITHDRAWAL DURING THE FIRST YEAR AFTER RENAL TRANSPLANTION IN MYCOPHENOLATE MOFETIL AND CYCLOSPORINE TREATED PATIENTS (1999) (6)
Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR) (2019) (6)
Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients (2020) (6)
Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series. (2009) (6)
Discovering novel injury features in kidney transplant biopsies associated with TCMR and donor aging (2020) (6)
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients (2019) (6)
Renal transplantation in the elderly. (2015) (6)
Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: The HERAKLES Study: 1675 (2012) (6)
FK506, transforming growth factor-beta1 and mesangial matrix synthesis: parallels and differences compared with cyclosporine A. (2006) (6)
Lessons from the CAESAR Study: Calcineurin Inhibitors—Can't Live with Them and Can't Live without Them (2007) (6)
Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine (1999) (5)
Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial (2022) (5)
Cyclosporin C2hour monitoring after renal transplantation. (2003) (5)
Sirolimus Dosage during and after Conversion from Calcineurin Inhibitor Therapy to Sirolimus in Chronic Kidney Transplant Patients (2004) (5)
Kidney transplantation at the Charité: long tradition, elderly patients and the duration of hospitalization. (2002) (5)
Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases (2020) (5)
Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19 (2022) (5)
Perioperative antibiotic prophylaxis in renal transplantation: a single-center comparison between two regimens and a brief survey among the Eurotransplant renal transplantation centers (2018) (5)
Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus–Associated Membranoproliferative Glomerulonephritis (2017) (5)
TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex (2021) (5)
A Domain-adapted Dependency Parser for German Clinical Text (2018) (5)
STEROID-FREE IMMUNOSUPPRESSION WITH DACLIZUMAB, TACROLIMUS AND MMF IS EFFICACIOUS AND IMPROVES CHOLESTEROL, GLUCOSE AND BONE MINERAL DENSITY – THE CARMEN STUDY (2004) (5)
Surrogate Endpoints for Late Kidney Transplantation Failure (2022) (5)
Determination of unacceptable HLA antigen mismatches in kidney transplant recipients (2021) (5)
PHARMACOKINETIC AND PHARMACODYNAMIC COMPARISON OF AN INITIALLY INTENSIFIED DOSING REGIMEN VERSUS A STANDARD DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT PATIENTS.: 717 (2008) (5)
Development of Graft-Site Candidiasis in 3 Solid Organ Transplant Recipients from the Same Donor (2017) (5)
IMPDH ACTIVITY ON DAY 6 AFTER KIDNEY TRANSPLANTATION IS SIGNIFICANTLY RELATED TO THE RISK OF ACUTE REJECTION IN MMF TREATED PATIENTS: 714 (2008) (5)
Impact of cyclosporine on the development of immunosuppressive therapy. (2004) (5)
[Kidney donors and kidney transplantation in the elderly]. (2004) (5)
Monitoring of gene expression in tacrolimus‐treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study (2021) (5)
SAFETY AND EFFICACY OF REDUCED OR FULL DOSE OF CYCLOSPORINE (NEORAL®) IN COMBINATION WITH MYCOPHENOLATESODIUM (MYFORTIC®), BASILIXIMAB (SIMULECT®), AND STEROIDS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS (2004) (5)
Desensitization of HLA-incompatible kidney recipients. (2011) (5)
Cross-over kidney transplantation with simultaneous laparoscopic living donor nephrectomy: initial experience. (2008) (5)
Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients (2021) (5)
Evaluating candidates for kidney transplantation: some recommendations still lack convincing clinical evidence. (2003) (5)
Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 36.: Abstract# 716 (2014) (5)
S 1 P modulator FTY 720 limits matrix expansion in acute anti-thy 1 mesangioproliferative glomerulonephritis (2007) (5)
Fate of Finally Transplanted Deceased Donor Kidneys Initially Rejected at Other Kidney Transplantation Centers (2014) (5)
Novel approaches to sarcopenic obesity and weight management before and after kidney transplantation (2020) (5)
Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A. (2006) (5)
Successful steroid withdrawal at the end of the 1st year after renal transplantion in mycophenolate mofetil-treated patients. (2002) (4)
Body Mass Index Thresholds and the Use of Bariatric Surgery in the Field of Kidney Transplantation in Germany (2022) (4)
Current status of immunosuppressive minimization and tolerance strategies (2015) (4)
The relationship between proteinuria and allograft survival in patients with transplant glomerulopathy: a retrospective single‐center cohort study (2020) (4)
The selective biomarker IL-8 identifies IFTA after kidney transplantation in blood cells. (2016) (4)
Efficacy and Safety of Three Different Treatment Regimens in de Novo Renal Transplant Patients: Results of the HERAKLES Trial: 1722 (2012) (4)
Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus–Positive Kidney Transplant Recipients (2019) (4)
Living donor nephrectomy--no impact of genetic relationship. (2003) (4)
What happens after graft loss? A large, long‐term, single‐center observation (2021) (4)
Donor-derived cell-free DNA as a diagnostic tool in transplantation (2022) (4)
Patient-Reported Outcomes as Endpoints in Clinical Trials of Kidney Transplantation Interventions (2022) (4)
Human leukocyte antigen-incompatible kidney transplantation after "desensitization"--hope and reality. (2014) (4)
Long-term results of conversion from existing to microemulsion formulation of cyclosporine. (1996) (4)
PD04-03 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TSC OR SLAM: FINAL LONG-TERM RESULTS FROM EXIST-2 (2016) (4)
757 Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Final long-term results from EXIST-2 (2016) (4)
Influence of pretransplant class I and II non-donor-specific anti-HLA immunization on immunologic outcome and graft survival in kidney transplant recipients. (2020) (4)
Assertion Detection in Clinical Notes: Medical Language Models to the Rescue? (2021) (4)
Sirolimus in renal transplant recipients with malignancies in Germany (2020) (4)
Steroid withdrawal in long-term cyclosporine A treated patients using mycophenolate mofetil: a prospective randomized pilot study. (2001) (4)
Predictors of graft survival at diagnosis of antibody‐mediated renal allograft rejection: a retrospective single‐center cohort study (2020) (4)
Obesity, Fat Tissue Parameters, and Arterial Stiffness in Renal Transplant Recipients. (2020) (4)
Information Extraction Models for German Clinical Text (2020) (4)
Bortezomib‐Based Antibody Reduction Therapy: The First Step to “True” Desensitization? (2015) (4)
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial (2022) (4)
BK virus infection: an update on diagnosis and treatment (2015) (4)
High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation. (2018) (3)
Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation (2022) (3)
Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study (2018) (3)
[Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation - An update of existing recommendations]. (2011) (3)
PRETREATMENT WITH FTY‐720 PROTECTS RENAL ALLOGRAFTS AGAINST PRESERVATION‐REPERFUSION INJURY.: Abstract# 62 (2000) (3)
Cytomegalievirus bei Nierentransplantation – Diagnose, Prävention und Management (2015) (3)
Enteric‐Coated Mycophenolate Sodium (EC‐MPS) and Mycophenolate Mofetil (MMF), it is Better to Have the Choice (2005) (3)
[Immunosuppression and its use in kidney transplantation]. (2015) (3)
Why rejections are not biopsy proven: frequency and reasons. (2010) (3)
Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection (2021) (3)
Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients (2022) (3)
Alloimmune Risk Stratification for Kidney Transplant Rejection (2022) (3)
Extended Criteria Donors in Living Kidney Transplantation Including Donor Age, Smoking, Hypertension and BMI (2020) (3)
PROBLEMS OF CYCLOSPORINE ABSORPTION PROFILING USING C2-MONITORING (2004) (3)
[Modern immunosuppression following renal transplantation. Standard or tailor made?]. (2006) (3)
Antibody therapy in steroid-resistant rejection. (1998) (3)
[Evaluation and follow-up of living kidney donors]. (2004) (3)
CONVERSION FROM TACROLIMUS TO EVEROLIMUS DOES NOT INFLUENCE THE PHARMACOKINETIC BUT INCREASES PHARMACODYNAMIC RESPONSE OF MYCOPHENOLATE SODIUM IN RENAL TRANSPLANT PATIENTS. (2006) (3)
About incidence and timing of donor-specific antibodies after graft nephrectomy. (2012) (3)
STEADY-STATE PHARMACOKINETICS AND TOLERABILITY OF RAD AND ITS INFLUENCE ON CYCLOSPORINE IN STABLE RENAL TRANSPLANT PATIENTS (1999) (3)
Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. (2021) (3)
Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. (1998) (3)
Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease. (2017) (3)
Prostaglandin E1 inhibits cyclosporine A-induced upregulation of transforming growth factor-beta 1 in rat mesangial cells (2001) (3)
IMPACT OF DACLIZUMAB AND LOW DOSE CYCLOSPORINE IN COMBINATION WITH MYCOPHENOLATE MOFETIL AND STEROIDS ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION (2004) (3)
Kidney Perfusion in Contrast-Enhanced Ultrasound (CEUS) Correlates with Renal Function in Living Kidney Donors (2022) (3)
Poor Long-Term Renal Allograft Survival in Patients with Chronic Antibody-Mediated Rejection, Irrespective of Treatment—A Single Center Retrospective Study (2021) (3)
Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation. (2015) (3)
Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantation. (1998) (3)
Efficacy and Safety of Three Different Treatment Regimens in De Novo Renal Transplant Patients: Month 36 Follow-Up Results of HERAKLES Trial.: Abstract# 718 (2014) (3)
The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation (2022) (3)
No Evidence for a Relationship Between Infiltrates in Renal Protocol Biopsies and Outcome (2007) (3)
Is a Retroaortic Vein a Risk Factor in Laparoscopic Living Donor Nephrectomy? (2020) (3)
PHARMACODYNAMIC MONITORING OF MYCOPHENOLATE MOFETIL BY MEASUREMENT OF IMPDH ACTIVITY.: Abstract# 87 (2000) (3)
Erratum: Building a network of ADPKD reference centres across Europe: the EuroCYST initiative(Nephrology Dialysis Transplantation) (2014) 29 :suppl 4 (iv26-iv32) doi: 10.1093/ndt/gfu091) (2014) (3)
Outcomes of Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program with A Focus on Recipients ≥75 Years (2021) (3)
Impact of Early Pancreatic Graft Loss on Outcome after Simultaneous Pancreas–Kidney Transplantation (SPKT)—A Landmark Analysis (2021) (3)
Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Results from EXIST-2. (2012) (3)
Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial (2020) (3)
Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation (2022) (3)
Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe (2022) (2)
Efficacy and complications of regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients with COVID-19 (2021) (2)
LONG-TERM SAFETY AND EFFICACY AFTER CONVERSION FROM MYCOPHENOLATE MOFETIL (MMF) TO ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS, MYFORTIC®) (2004) (2)
The impact of FTY 720 ( fingolimod ) on vasodilatory function and arterial elasticity in renal transplant patients (2007) (2)
Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation (2022) (2)
Living Donor Transplantation: Long-Term Evolution Related to Age Matching. (2015) (2)
Different diagnostic approaches to adult candidates for cadaveric kidney transplantation in Europe (2000) (2)
Designation of T-cell-mediated rejection type Ib and IIa reflects the type of rejection rather than the severity in the Banff classification. (2014) (2)
ANALYSIS OF CONVERSION FROM MYCOPHENOLATE MOFETIL TO ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS, MYFORTIC) IN RENAL TRANSPLANT PATIENT USING PATIENT-REPORTED OUTCOMES: 974 (2008) (2)
Invited letter in response to “Predicted indirectly recognizable HLA epitopes (PIRCHE): Only the tip of the iceberg?” (2018) (2)
Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation. (1998) (2)
POLYMORPHISMS IN THE URIDINE DIPHOSPHATE (UDP)-GLUCURONOSYLTRANSFERASES (UGT) GENE EXPLAIN PART OF THE INTER-INDIVIDUAL VARIABILITY IN MYCOPHENOLATE MOFETIL (MMF) PHARMACOKINETICS. (2006) (2)
Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function. (1998) (2)
ANTI-IL-6 ANTIBODY CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION – MOLECULAR REBOUND PHENOMENA UNDER IL-6 BLOCKADE? (2020) (2)
Development and validation of multivariable prediction models of serological response to SARS-CoV-2 vaccination in kidney transplant recipients (2022) (2)
De novo Renal Transplantation after Kaposi Sarcoma: Favorable Outcome in a Patient Receiving Sirolimus and Mycophenolate-Based Immunosuppression (2010) (2)
suPAR in Transplant Patients With FSGS Recurrence.: Abstract# 1407 (2014) (2)
The The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients - a cross-sectional prospective observational clinical study. (2020) (2)
Renal Function of an Everolimus Based Therapy after Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients: 3 Year Data of the APOLLO Trial: 1684 (2012) (2)
CONVERSION FROM CYCLOSPORINE TO EVEROLIMUS LEADS TO BETTER RENAL FUNCTION AND TO PROFOUND CHANGES IN EVEROLIMUS AND MYCOPHENOLATE METABOLISM (2006) (2)
Influence of lipid profile and statin administration on arterial stiffness in renal transplant recipients (2020) (2)
Should We Perform Old-For-Old Kidney Transplantation during the COVID-19 Pandemic? The Risk for Post-Operative Intensive Stay (2020) (2)
Outcome On Renal Function of an Everolimus Based Therapy After Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients: 5 Year Data of the APOLLO Trial.: Abstract# 2920 (2014) (2)
Tacrolimus only for breakfast … * (2012) (2)
Rapid Attainment of Tacrolimus Trough Levels Early Post-Transplant Reduces Risk of Treatment Failure in De Novo Kidney Transplant Patients: A Covariate Analysis of a Phase 3 Double-Blind Study.: Abstract# A210 (2014) (2)
AN ADJUVANTED INFLUENZA A H1N1 VACCINE (PANDEMRIX®) DOES NOT PROVIDE A PROTECTIVE IMMUNE RESPONSE IN THE MAJORITY OF RENAL TRANSPLANT RECIPIENTS: 3225 (2010) (2)
LB2307. Safety and Efficacy of Letermovir (LET) versus Valganciclovir (VGCV) for Prevention of Cytomegalovirus (CMV) Disease in Kidney Transplant Recipients (KTRs): A Phase 3 Randomized Study (2022) (2)
mHealth und digitales Management nach Nierentransplantation (2017) (2)
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform. (2021) (2)
When performance is not enough—A multidisciplinary view on clinical decision support (2022) (2)
[Ten years of laparoscopic living kidney donation. From an extravagant to a routine procedure]. (2006) (2)
The natural history of de novo donor-specific HLA antibodies after kidney transplantation (2022) (2)
Immunologic Long-term Outcomes of Living-Related Kidney Transplantations Depending on the Donor-Recipient Relationship. (2017) (2)
Conversion From Tacrolimus to Cyclosporine A Improves Glucose Metabolism in Patients With New Onset Diabetes After Transplantation: Interim Analysis of a Prospective and Randomized Study.: Abstract# 1393 (2014) (2)
Digitale Nephrologie (2019) (2)
Correction to: The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation (2021) (2)
1 Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC) from EXIST-2: Continued efficacy and diminishing adverse events after ∼3.5 years of treatment (2015) (2)
Authors' Reply: SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Should We Consider Intradermal Vaccination? (2022) (2)
Intensive monitoring of post filter ionized calcium concentrations during CVVHD with regional citrate anticoagulation: A retrospective study. (2020) (2)
Sporadische Lymphangioleiomyomatose (sLAM) und Tuberöse-Sklerose-Komplex (TSC) – Pulmonale Manifestationen (2016) (2)
1139 Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC): EXIST-2 3-year follow-up (2014) (2)
Nephrologistsʼ Preferences and Perspectives On Patientsʼ Access to Kidney Transplantation: A Systematic Review.: Abstract# B834 (2014) (2)
Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2. (2012) (2)
CONVERSION FROM CYCLOSPORINE TO EVEROLIMUS LEADS TO BETTER RENAL FUNCTION AND TO PROFOUND CHANGES IN EVEROLIMUS AND MYCOPHENOLATE METABOLISM (2006) (2)
Overview on Clinical Trials and Resistance Breaking Activity of the Anti-Cytomegalovirus Compound AIC246 (2010) (2)
Renal cancer and the kidney in cancer (2012) (1)
Impact of COVID-19 on Global Kidney Transplantation Service Delivery: Interim Report (2022) (1)
Late Steroid Withdrawal Following AB0-Incompatible Renal Transplantation. (2018) (1)
Analysis of Factors Affecting Employment Status of Kidney Transplant Recipients in Selected European Union Member States (2021) (1)
MULTI-CENTER, OPEN-LABEL, PROSPECTIVE, RANDOMIZED, PARALLEL GROUP STUDY INVESTIGATING AN EVEROLIMUS-BASED CNI-FREE REGIMEN IN COMPARISON TO A CYCLOSPORINE-BASED STANDARD THERAPY IN DE NOVO RENAL TRANSPLANT PATIENTS (ZEUS STUDY): 1640 (2008) (1)
SaO043FROM DRY WEIGHT TO TARGET BLOOD VOLUME: A NEW APPROACH TO AUTOMATED VOLUME MANAGEMENT IN HAEMODIALYSIS (2018) (1)
Post Hoc Analysis of ZEUS and HERAKLES, Two Prospective, Open-Label, Multicenter, Randomized Trials: Onset and Progression of Diabetes in Kidney Transplant Recipients On Cyclosporine Standard or Converted to CNI-Free or CNI-Low Everolimus Regimen.: Abstract# 2921 (2014) (1)
POOLED ANALYSIS OF THREE PROSPECTIVE, 12-MONTH, MULTICENTER STUDIES OF ENTERIC-COATED MYCOPHENOLATE SODIUM (MYFORTIC®) IN DE NOVO RENAL TRANSPLANT PATIENTS. (2006) (1)
Kidney graft function and arterial stiffness in renal transplant recipients. (2021) (1)
Analysis of Risk Factors and Long-Term Outcomes in Kidney Transplant Patients with Identified Lymphoceles (2020) (1)
Clinicopathologic Features and Risk Factors of Proteinuria in Transplant Glomerulopathy (2021) (1)
Urinary CD8+HLA-DR+ T Cell Abundance Non-invasively Predicts Kidney Transplant Rejection (2022) (1)
12 MONTH FOLLOW UP RESULTS OF AN INITIAL INTENSIFIED DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN DE NOVO RENAL TRANSPLANT RECIPIENTS (2011) (1)
Superior Long-Term Efficacy of Bortezomib Combined With High Dose IVIG in Contrast to Rituximab Based Antibody-Mediated Rejection Therapy in Renal Transplant Patients - A Comparative Retrospective Analysis.: Abstract# 2893 (2014) (1)
Remote Patient Management May Reduce All-Cause Mortality in Patients With Heart-Failure and Renal Impairment (2022) (1)
Prostaglandin E(1) inhibits cyclosporine A-induced upregulation of transforming growth factor-beta 1 in rat mesangial cells. (2001) (1)
haemodia fi ltration : de fi nition , dose quanti fi cation and safety revisited (2013) (1)
IMPDH ACTIVITY IS CORRELATED WITH THE 3757T>C POLYMORPHISM IN THE IMPDH TYPE 2 GENE IN MMF TREATED KIDNEY TRANSPLANT PATIENTS: 104 (2008) (1)
THE RAPAMYCIN ANALOGUE SDZ RAD INHIBITS LPS AND ANTI‐CD3mAb INDUCED IL‐10 SYNTHESIS IN VITRO AND IN HUMAN RENAL ALLOGRAFT RECIPIENTS.: Abstract# 956 (2000) (1)
EC-MPS IS ASSOCIATED WITH SUPERIOR EFFICACY OUTCOMES COMPARED WITH MMF IN DE NOVO RENAL TRANSPLANT RECIPIENTS (RTXR): A POOLED ANALYSIS: 558 (2010) (1)
Three-Year Outcomes in Patients with Delayed Graft Function in Phase III Studies of Belatacept Vs Cyclosporine in Kidney Transplantation (BENEFIT and BENEFIT-EXT): 1853 (2012) (1)
INITIAL INTENSIFIED DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) VERSUS STANDARD DOSING IMPROVES REJECTION PROPHYLAXIS IN DE NOVO RENAL TRANSPLANT RECIPIENTS: 1592 (2010) (1)
PD17-01 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX: EXIST-2 LONG-TERM EFFICACY AND SAFETY (2014) (1)
Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation (2022) (1)
Donor-Derived Cell-free DNA for Personalized Immunosuppression in Renal Transplantation (2022) (1)
Sotrastaurin + Reduced-Exposure Tacrolimus Prevents Acute Rejecton and Preserves Renal Function after De Novo Kidney Transplantation - 12 Month Results: 945 (2012) (1)
A Medical Information Extraction Workbench to Process German Clinical Text (2022) (1)
Case-based reasoning algorithm for kidney transplant monitoring. (2001) (1)
AN INTENSIFIED DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM IN RENAL TRANSPLANT PATIENTS RESULTS IN IMPROVED EFFICACY WITHOUT COMPROMISING SAFETY: 1 YEAR FOLLOW-UP RESULTS: 1709 (2010) (1)
981 Predictive value of angiogenic biomarkers in tuberous sclerosis complex (TSC) patients with renal angiomyolipoma (AML) (2013) (1)
Outcomes at 3 Years in EBV+ European Subpopulations From BENEFIT and BENEFIT-EXT.: Abstract# A198 (2014) (1)
COMPARABLE PATIENT REPORTED OUTCOMES WITH INITIALLY INTENSIFIED DOSING VERSUS STANDARD DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN DE NOVO RENAL TRANSPLANT RECIPIENTS: 1571 (2010) (1)
Evaluation of severity of delayed graft function in kidney transplant recipients. (2021) (1)
SaO014USE OF A MOBILE APP TO IMPROVE MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS - A PROSPECTIVE INTERVENTIONAL STUDY (2018) (1)
Post Hoc Subgroup Analysis of ZEUS: Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen.: Abstract# C1917 (2014) (1)
Evaluation of the Effectiveness of Interventions on Nephrolithiasis in Transplanted Kidney. (2022) (1)
Low-dose rapamycin does not impair vascular integrity and tubular regeneration after kidney transplantation in rats (2021) (1)
Declining Course of Humoral Immune Response in Initially Responding Kidney Transplant Recipients after Repeated SARS-CoV-2 Vaccination (2022) (1)
Poor Outcomes in Patients With Transplant Glomerulopathy Independent of Banff Categorization or Therapeutic Interventions (2022) (1)
PD35-10 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX: EFFICACY AND SAFETY AFTER 3.5 YEARS OF TREATMENT IN THE EXIST-2 STUDY (2015) (1)
Rationale, design and statistical analysis of a prospective randomized trial comparing initially intensified vs standard dose regimens of enteric-coated mycophenolate sodium in De novo renal transplant patients (2007) (1)
The risk of tumour recurrence in patients undergoing renal transplantation for endstage renal disease after previous treatment for a urological cancer: A systematic review (2018) (1)
Sporadische Lymphangioleiomyomatose (sLAM) und Tuberöse-Sklerose-Komplex (TSC) – Pulmonale Manifestationen (2016) (1)
Two-Year Results of Envarsus (Once-Daily MeltDose Tacrolimus Tablets) vs Prograf (Twice-Daily Tacrolimus Capsules): A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study.: Abstract# A2978 (2014) (1)
LOW SEROPREVALENCE OF SARS-COV-2 ANTIBODIES DURING SYSTEMATIC SCREENING FOR COVID-19 INFECTION IN A GERMAN COHORT OF KIDNEY TRANSPLANT RECIPIENTS (2020) (1)
An Annotated Corpus of Textual Explanations for Clinical Decision Support (2022) (1)
Suggested guidelines for reporting clinical results in transplantation trials (2007) (1)
80 Everolimus in the treatment of angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Results from EXIST-2 (2012) (1)
Does the Side Matter? A Retrospective Cohort Study Comparing Left and Right Pure Laparoscopic Donor Nephrectomies (2021) (1)
Everolimus for the Treatment of Angiomyolipoma in Patients with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis: Results from EXIST-2 (P04.188) (2012) (1)
SP757The Burden of Delayed Graft Function on Kidney Transplant Recipients and Impact on long-term outcomes (2019) (0)
CMV Seroconversion During Prolonged Prophylaxis With Valgancyclovir in D+/R- Kidney Transplant Recipients Prevents CMV Disease: Long-Term Follow-Up.: Abstract# D2368 (2014) (0)
Complement-binding anti-HLA antibodies and kidney transplantation. (2014) (0)
The Effect of Acute Rejection Episodes According to Banff 2009 on Long-Term Outcome of Patients after Kidney Transplantation: 1010 (2012) (0)
MP700IMPACT OF PRE-EXISTING DIABETES MELLITUS TYPE 2 AND POST-TRANSPLANT HBA1CIN KIDNEY TRANSPLANTATION (2016) (0)
INFLUENCE OF PREFORMED DONORSPECIFIC HLA-ANTIBODIES ON KIDNEY TRANSPLANTATION - FIRST RESULTS OF A MULTICENTER RETROSPECTIVE STUDY (2016) (0)
TO016CLINICAL PHARMACOKINETICS OF SOFOSBUVIR AND DACLATASVIR IN KIDNEY TRANSPLANT RECIPIENTS (2017) (0)
Dialysis Transplantation Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients : results after 1 year (2005) (0)
Long-Term Outcome of Critically Ill Renal Transplant Recepients After Admission to Intensive Care Unit: A 5-Year Follow-Up.: Abstract# 638 (2014) (0)
SP781INFLUENCE OF BELATACEPT- VS. CNI-BASED IMMUNOSUPPRESSION ON VASCULAR STIFFNESS AND CELL FUNCTION (2019) (0)
Leucopenia in the First Year After Renal Transplantation During Valganciclovir Prophylaxis.: Abstract# D2414 (2014) (0)
Differences in reporting of acute rejections between American and European publications of large immunosuppressive trials impair comparability of study results. (2005) (0)
SP730THE EFFECT OF DELAYED GRAFT FUNCTION ON LONG TERM GRAFT SURVIVAL STRATIFIED BY KDPI BASED DONOR KIDNEY QUALITY CATEGORIES (2017) (0)
TCRM_A_256962 787..793 (2020) (0)
Influence of Belatacept- vs. CNI-Based Immunosuppression on Vascular Stiffness and Body Composition (2022) (0)
Stress-Induced Peritoneal Endothelin-1 Release in Continuous Ambulatory Peritoneal Dialysis (1999) (0)
Short Presentations on Posters (2016) (0)
316 Pre-operative assessment of living renal transplant donors with state-of-the-art imaging modalities: Computed tomography angiography vs. magnetic resonance angiography in 118 patients (2012) (0)
OP-NDTJ180393 1597..1611 (2019) (0)
Determinants of Successful Use of Sirolimus in Renal Transplant Patients. (2020) (0)
FTY720 VS. MYCOPHENOLATE MOFETIL, ECONOMIC IMPACT IN CYCLOSPORINE BASED IMMUNOSUPRESSION FOR DE NOVO RENAL TRANSPLANTATION (2004) (0)
INITIALLY INTENSIFIED DOSING REGIMEN OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) OFFERS EARLY ADEQUATE MYCOPHENOLIC ACID (MPA) EXPOSURE IN DE NOVO RENAL TRANSPLANT RECIPIENTS: 1547 (2010) (0)
IMP-Dehydrogenase in Erythrocytes for Detection of Non-Adherence to MPA Therapy: 2271 (2012) (0)
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection (authors reply inN Engl J Med. 2005 May 12;352(19):2027-8) (2005) (0)
Related articles (2014) (0)
Criteria for prediabetes and posttransplant diabetes mellitus after kidney transplantation: A 2‐year diagnostic accuracy study of participants from a randomized controlled trial (2022) (0)
Renal transplantation - clinical studies - 2 (2009) (0)
Explorative analysis of zeus after 5 years: histological assessment from biopsy analyses (2015) (0)
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection — NEJM (2014) (0)
Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project (2020) (0)
Effect of Everolimus on Subependymal Giant Cell Astrocytoma in Patients Being Treated for Renal Angiomyolipoma: Final Results from EXIST-2 (S34.005) (2016) (0)
Management of Immunosuppression in Critically Ill Renal Transplant Patients in the ICU: Immunologic and Overall Long-Term Outcome.: Abstract# B971 (2014) (0)
FULL DOSE MYCOPHENOLATE MOFETIL (CELLCEPT®) WITH LOW DOSE TACROLIMUS OPTIMIZES RENAL FUNCTION IN LONG TERM RENAL TRANSPLANT PATIENTS; RESULTS OF THE TRANCEPT STAY STUDY: 1711 (2010) (0)
SP740LYMPHOCELES IN KIDNEY TRANSPLANT RECIPIENTS: INCIDENCE, RISK FACTORS AND IMPACT ON LONG-TERM OUTCOMES (2017) (0)
Optimization of Therapy with Mycophenolic Acid After Kidney Transplantation (2011) (0)
FP837BODY MASS INDEX (BMI) MISMATCH IN DECEASED KIDNEY DONATION IS AN INDEPENDENT RISK FACTOR FOR GRAFT FAILURE (2015) (0)
Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10 (2022) (0)
ACCURATE PREDICTION OF KIDNEY ALLOGRAFT OUTCOME BASED ON CREATININE COURSE IN THE FIRST YEAR POST-TRANSPLANT (2004) (0)
Effects of Sotrastaurin, Mycophenolic Acid and Everolimus on Human B-Lymphocyte Function and Activation: 612 (2012) (0)
FP870HLA-DR MATCHING IMPROVES IMMUNOLOGIC OUTCOMES IN ELDERLY KIDNEY TRANSPLANT RECIPIENTS (2015) (0)
Contents Vol. 93, 2014 (2014) (0)
Kidney Transplant Survival In Patients With Preformed Donor-Specific HLA Antibodies In Solid-Phase Assays (2017) (0)
Assessment of Renal Transplant Perfusion by Contrast-Enhanced Ultrasound after Switch from Calcineurin Inhibitor to Belatacept: A Pilot Study (2022) (0)
SO025DONOR RECIPIENT MATCHING BASED ON HLA EPITOPES IMPROVES OUTCOME IN KIDNEY TRANSPLANT RECIPIENTS (2017) (0)
The Clinical Data Intelligence Project (2015) (0)
Explorative post hoc analysis of zeus after 5 years: histological assessments from biopsies (2015) (0)
MO105TELEMEDICAL SURVEILLANCE AND OPTIMIZED TREATMENT OF BLOOD PRESSURE IN KIDNEY TRANSPLANT RECIPIENTS (2021) (0)
No association of renin-angiotensin system gene polymorphisms with delayed graft function, acute rejection episodes and long-term graft dysfunction in kidney transplant recipients (2002) (0)
Updated safety results from EXIST-2 (2012) (0)
Range and Consistency of Cardiovascular Outcomes Reported by Clinical Trials in Kidney Transplant Recipients: A Systematic Review (2022) (0)
Hypertension in renal allograft recipients. (1999) (0)
ANALYZING CAUSES FOR DEATH-CENSORED ALLOGRAFT FAILURE IN KIDNEY TRANSPLANT RECIPIENTS (2020) (0)
LONG-TERM, BUT LOW DOSE ORAL GANCICLOVIR CYTOMEGALOVIRUS (CMV) PROPHYLAXIS – AN ALTERNATIVE STRATEGY FOR KIDNEY TRANSPLANT RECIPIENTS (2004) (0)
SP727VERY HIGH KDPI KIDNEYS IN ELDERLY TRANSPLANT RECIPIENTS - NO NEED TO DISCARD (2017) (0)
SP677HOW DO PRE-EXISTING COMORBIDITIES INFLUENCE LONG-TERM PATIENT AND GRAFT SURVIVAL AND THE IMMUNOLOGIC OUTCOME IN KIDNEY TRANSPLANT RECIPIENTS? - AN EVALUATION OF COMORBID CONDITIONS (2016) (0)
ASSESSMENT OF T CELL FUNCTION AND T CELL ACTIVATION IN HEALTHY VOLUNTEERS, DIALYSIS AND RENAL-TRANSPLANT PATIENTS BY USING A WHOLE BLOOD FACS ASSAY. (2006) (0)
FTY720 PHARMACOKINETICS, LYMPHOCYTE COUNTS, AND REJECTION INCIDENCE IN A PHASE 3 KIDNEY TRANSPLANT TRIAL. (2006) (0)
MP727COMPLETE RECOVERY OF KIDNEY ALLOGRAFT FUNCTION AFTER RECURRENCE OF HCV RELATED MPGN: A CASE OF SUCCESSFUL ANTIVIRAL TREATMENT OF HCV IN A KIDNEY ALLOGRAFT RECIPIENT REQUIRING HEMODIALYSIS (2016) (0)
IMPACT OF NON-ACTIVE HEPATITIS B ON PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION (2020) (0)
MO022IMMUNOLOGIC OUTCOME AFTER KIDNEY TRANSPLANTATION DEPENDS ON DONOR FACTORS AND DECEASED DONOR KIDNEY ASSOCIATED RISK ASSESSED BY THE KIDNEY DONOR PROFILE INDEX (KDPI) (2016) (0)
MO938PATIENT SURVIVAL AFTER LIVING DONOR KIDNEY DONATION (2021) (0)
THREE-MONTH RESULTS OF A PHASE 2 TRIAL EVALUATING CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION – EARLY IMPACT OF IL-6 BLOCKADE ON DONOR-SPECIFIC ANTIBODY LEVELS, REJECTION MORPHOLOGY AND GENE EXPRESSION (2020) (0)
Concurrent Oral Sessions: Late Breaking (2014) (0)
FP834IMPACT OF PREGNANCIES ON IMMUNIZATION AND OUTCOME IN KIDNEY TRANSPLANTATION (2015) (0)
Aspect-Based Passage Retrieval with Contextualized Discourse Vectors (2021) (0)
SP667POST-TRANSPLANTAT SURVIVAL OF KIDNEY TRANSPLANT RECIPIENTS IS SIGNIFICANTLY IMPAIRED BY PRE-TRANSPLANT CORONARY ARTERY DISEASE (2016) (0)
Artificial Intelligence in Outpatient Care in Times of Covid-19: A Multidisciplinary Comment on the Impact of a Notional Artificial Intelligence Based Clinical Decision Support System on Outpatient Care for Kidney Transplant Recipients (Preprint) (2020) (0)
[Treatment of hypercholesterolemia in kidney transplant recipients]. (2003) (0)
FP156ASSESSMENT OF ARTERIAL STIFFNESS IN RENAL TRANSPLANT RECIPIENTS (2019) (0)
Transplantation - clinical II (2012) (0)
Updated safety results from EXIST-2: Everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM). (2012) (0)
Pharmacodynamics of mycophenolate mofetil in renal allograft recipients (2001) (0)
TO002ADJUSTMENT OF DRY WEIGHT BASED ON ABSOLUTE BLOOD VOLUME REDUCES THE FREQUENCY OF INTRADIALYTIC MORBID EVENTS (2017) (0)
Presidential & Awards Session (2011) (0)
1302 EXIST-2: EFFECT OF EVEROLIMUS ON ANGIOMYOLIPOMA IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX OR SPORADIC LYMPHANGIOMYOMATOSIS (2012) (0)
SO015KDPI DEPENDENT OUTCOMES AND DISCARD RATES - A COMPARISON OF EUROPEAN AND U.S. RESULTS (2016) (0)
FP713DE NOVO MALIGNANCIES AFTER KIDNEY TRANSPLANTATION: A LONG-TERM OBSERVATIONAL STUDY (2018) (0)
Pretransplant PRA and Long-Term Outcomes of Kidney Transplant Recipients: 1619 (2012) (0)
Post hoc subgroup analysis of zeus: outcome on renal function, efficacy and safety in living-donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen: 5 year follow-up data (2015) (0)
PREVENTION OF A HEALTH CARE CRISIS ENABLES RESOURCES FOR CONTINUING ORGAN TRANSPLANTATION DURING COVID-19 PANDEMIC (2020) (0)
Immune response to an adjuvanted inﬂuenza A H1N1 vaccine (Pandemrix (cid:3) ) in renal transplant recipients (2012) (0)
SP721Evaluation of Main Diagnoses of Kidney Transplant Recipients and DRG-Costs in German Health Care System (2019) (0)
Barriers to online consultation in nephrological care: An online-survey among nephrologists. (2021) (0)
Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease (2015) (0)
Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy (2016) (0)
Dialysis and pregnancy - A series of five cases of pregnancy with intensified dialysis (2008) (0)
Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena (2022) (0)
Once-Daily Envarsus Demonstrates Comparable Efficacy and Safety to Twice-Daily Prograf: A Phase 3 Study for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients.: Abstract# 2160 (2014) (0)
IMPACT OF THE CYP3A5 *1/*3 ALLELES ON THE PHARMACOKINETICS OF TWO TACROLIMUS FORMULATIONS AFTER RENAL TRANSPLANTATION: 2512 (2010) (0)
MP725EXTENDED RELEASE TACROLIMUS IN KIDNEY ALLOGRAFT RECIPIENTS - PHARMACOKINETIC AND ECONOMICAL ASPECTS (2016) (0)
SP003Diagnostic Yield of NGS-based Panel Testing among Waitlisted Patients (2019) (0)
RENAL TRANSPLANT PATIENTS RECEIVING MMF WITH TACROLIMUS SHOWS SIMILAR PHARMACOKINETIC AND PHARMACODYNAMIC RESPONSE AFTER CONVERSION TO ENTERIC-COATED MYCOPHENOLATE SODIUM WITHOUT COMPROMISE IN TOLERABILITY AND EFFICACY. (2006) (0)
SP676IMPACT OF PRE-EXISTING CHRONIC HEART FAILURE ON PATIENT SURVIVAL, GRAFT FUNCTION AND IMMUNOLOGIC OUTCOME IN KIDNEY TRANSPLANTATION (2016) (0)
Pre-Operative Assessment of Living Renal Transplant Donors with State-Of-The-Art Imaging Modalities: Computed Tomography Angiography vs. Magnetic Resonance Angiography in 118 Patients: 312 (2012) (0)
Phylogeography of guineo-congolian forest plants: a first synthesis (2012) (0)
INCREASED FREQUENCY OF ANGIOEDEMA UNDER COMBINED TREATMENT WITH MTOR – AND ACE- INHIBITOR IN KIDNEY TRANSPLANTED PATIENTS: 1618 (2008) (0)
Body composition, food intake, and substrate oxidation after liver or kidney transplantation (1998) (0)
Renal Allograft Failure Due to Cardiorenal Syndrome.: Abstract# B899 (2014) (0)
Determinants of Outcome after KTX in Elderly Patients: 2365 (2012) (0)
SP747SUCCESSFUL HCV THERAPY WITH NOVEL DAA REGIMEN IMPROVES GLUCOSE TOLERANCE AND MAY PREVENT POST-TRANSPLANT DIABETES MELLITUS IN RENAL TRANSPLANT RECIPIENTS (2018) (0)
A Phase III Randomized Trial of Conversion to Once-Daily Extended Release Meltdose® Tacrolimus Tablets (LCP-Tacro™) from Twice-Daily Tacrolimus Capsules (Prograf®): Efficacy Results from an Analysis of Specific Patient Sub-Populations: 1165 (2012) (0)
MP785LONG-TERM OUTCOMES OF KIDNEY TRANSPLANT RECIPIENTS WITH FSGS (2017) (0)
Species delimitation, phylogeographic patterns and gene flow in Central African rain forest plants (2011) (0)
NT-PRO BNP, VISCERAL FAT AREA, CELL MEMBRANE INTEGRITY AND ARTERIAL STIFFNESS IN RENAL TRANSPLANT RECIPIENTS (2020) (0)
SP226INTENSIVE MONITORING OF POST-FILTER IONIZED CALCIUM DURING CVVHD WITH REGIONAL CITRATE ANTICOAGULATION (2019) (0)
MO943IMPACT OF NON-ACTIVE HEPATITIS B ON PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION (2021) (0)
SP734THE BREADTH AND CONSISTENCY OF OUTCOMES REPORTED IN RANDOMISED TRIALS CONDUCTED IN ADULT KIDNEY TRANSPLANT RECIPIENTS (2017) (0)
Transplanting HCV-Infected Kidneys into Uninfected Recipients. (2017) (0)
Renal transplantation - clinical studies - 3 (2009) (0)
SP688FACTORS ASSOCIATED WITH ACUTE REJECTIONS IN KIDNEY TRANSPLANT RECIPIENTS: TIME FOR HLA-DR MATCHING IN ELDERLY RECIPIENTS? (2016) (0)
Post-Transplantations-Diabetes mellitus nach Nierentransplantation (2013) (0)
SaO017EPITOPE MATCHING PREDICTS IMMUNIZATION AFTER ALLOGRAFT FAILURE CAUSING LONGER WAITING TIME FOR RE-TRANSPLANTATION (2019) (0)
Snowflake epitope matching correlates with child-specific antibodies during pregnancy and donor-specific antibodies after kidney transplantation (2022) (0)
SP827DIAGNOSTIC BRONCHOSCOPY IN KIDNEY TRANSPLANT RECIPIENTS WITH ACUTE RESPIRATORY FAILURE (2017) (0)
1459: Expanding the Donor Pool in Kidney Transplantation - 7 Years Experience with Eurotransplant Senior Program (2006) (0)
PHARMACODYNAMIC MONITORING OF DE NOVO RENAL TRANSPLANT RECIPIENTS UNDERGOING CONVERSION FROM CYCLOSPORINE TO EVEROLIMUS IN COMBINATION WITH MYCOPHENOLATE: 1200 (2008) (0)
FP790Malignancies after kidney transplantation: a long-term observational study (2019) (0)
Poster Sessions (2018) (0)
Determinants and Duration of Hospitalisations after KTX in Elderly Patients: 2264 (2012) (0)
STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany. (2021) (0)
Online Consultation in Nephrological Care - An Online-Survey Among Nephrologists (Preprint) (2020) (0)
SP725VALIDATION OF THE RISK INDEX FOR LIVING DONOR KIDNEY TRANSPLANTATION (LKDPI) IN A EUROPEAN COHORT (2017) (0)
SP633PROSPECTIVE LONG-TERM ANALYSIS OF B- AND PLASMA CELL SUBSETS IN RENAL TRANSPLANT PATIENTS AFTER TREATMENT WITH RITUXIMAB AND BORTEZOMIB IN ANTIBODY MEDIATED REJECTION (2016) (0)
EFFECTS OF THE NEW IMMUNOSUPPRESSIVE AGENT AEB071 ON HUMAN IMMUNE CELLS IN VITRO: 1218 (2008) (0)
FIRST APPLICATION OF EXPOSURE-RESPONSE MODELING TO OPTIMIZE CLINICAL OUTCOMES OF TASOCITINIB (CP-690,550) IN KIDNEY TRANSPLANT PATIENTS: PRELIMINARY RESULTS: 1135 (2010) (0)
Outcome on renal function, efficacy and safety in living-donor kidney transplant recipients after conversion from cni to everolimus-based regimen: 5 year data post hoc analysis from the zeus study (2015) (0)
INTERNATIONAL, MATCHED-COHORT CHECKERBOARD STUDY OF QUALITY OF LIFE AND DISEASE BURDEN IN KIDNEY TRANSPLANT (TX) PATIENTS WITH ANTIBODY-MEDIATED REJECTION (AMR) (2019) (0)
Patient And Graft Survival In Patients With Previous Malignancies After Conversion MTOR Inhibitor Sirolimus In A Large German Cohort (2017) (0)
Analysis of Risk Factors and Long-Term Outcomes in Kidney Transplant Patients with Identiﬁed Lymphoceles (2020) (0)
Renal failure from diabetic glomerulosclerosis three decades after allograft transplantation. (1999) (0)
Risks and benefits of everolimus (2019) (0)
Cytosorb® Rescue for COVID-19 Patients with Vasoplegic Shock (CytoResc): A Prospective, Open-Label, Randomised Controlled Pilot Study (2021) (0)
Six pills less: no benefit for bicarbonate supplementation in renal allograft recipients (2023) (0)
FTY720 MODULATES AKT [SER473] PHOSPHORYLATION IN HUMAN LYMPHOCYTES (2004) (0)
SO024DONOR RECIPIENT MATCHING BASED ON INDIRECTLY RECOGNIZABLE HLA EPITOPES INDEPENDENTLY PREDICTS OUTCOME AFTER KIDNEY TRANSPLANTATION (2017) (0)
SP658INFLUENCEOF PRETRANSPLANT CLASS I AND II NON-DONOR-SPECIFIC ANTI-HLA IMMUNIZATION ONIMMUNOLOGIC OUTCOME AND GRAFT SURVIVAL IN KIDNEY TRANSPLANT RECIPIENTS (2016) (0)
Transplantation: clinical studies - A (2013) (0)
Long-term investigation of hepatitis G virus infection in renal transplant recipients with and without hepatitis B and C co-infection. (1999) (0)
SAFETY AND EFFICACY OF ENTERIC-COATED MYCOPHENOLATE SODIUM VS. MYCOPHENOLATE MOFETIL IN MAINTENANCE DIABETIC KIDNEY TRANSPLANT PATIENTS. (2006) (0)
VASCULAR STIFFNESS PARAMETERS AFTER RENAL TRANSPLANTATION ARE DIFFERENT IN LONGTERM MTOR-BASED IMMUNOSUPPRESSION VERSUS CNI-BASED IMMUNOSUPRESSION: 1713 (2010) (0)
P0821OBESITY, FAT TISSUE, CELL MEMBRANE INTEGRITY PARAMETERS AND ARTERIAL STIFFNESS IN RENAL TRANSPLANT RECIPIENTS (2020) (0)
MO105 TELEMEDICAL SURVEILLANCE AND OPTIMIZED TREATMENT OF BLOOD PRESSURE IN KIDNEY TRANSPLANT RECIPIENTS THE AHUS (2021) (0)
Arterial Stiffness as a Cardiovascular Risk Factor After Successful Kidney Transplantation in Diabetic and Nondiabetic Patients. (2022) (0)
A single center in-depth analysis of death with a functioning kidney graft and reasons for overall graft failure. (2022) (0)
RENAL FUNCTION OF AN EVEROLIMUS BASED THERAPY AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS ONE YEAR AFTER CONVERSION: 1742 (2010) (0)
Diagnostic Utility of Exome Sequencing for Kidney Disease. (2019) (0)
8 Laparoscopic vs. open donor nephrectomy - impact on quality of life and willingness to donate (2004) (0)
AI in medicine and care from the perspective of patients (2020) (0)
FP816IMMUNOLOGIC LONG-TERM OUTCOME OF LIVING KIDNEY TRANSPLANTATION DEPENDING ON THE DONOR-RECIPIENT RELATIONSHIP (2015) (0)
Corrigendum: Three-Month follow-up of heterologous vs. homologous third SARS-CoV-2 vaccination in kidney transplant recipients: Secondary analysis of a randomized controlled trial (2022) (0)
Body composition and substrate oxidation in long-term survivors after transplantation of liver or kidney (1998) (0)
O.45 Body composition, subtrate intake and oxidation in long-term survivors after liver or kidney transplantation (1998) (0)
No influence of the MDR-1 C3435T polymorphism on cyclosporine absorption profiles and tacrolimus dosage or renal function in stable renal transplant recipients (2003) (0)
Clindamycin-Primaquine Is Safe in Treating Pneumocystis Pneumonia in Renal Transplant Patiens but Appears to Be Less Effective than Trimethoprim/Sulfamethoxazole: 2097 (2012) (0)
MP822DEVELOPING CONSENSUS BASED PRIORITY OUTCOME DOMAINS FOR TRIALS IN KIDNEY TRANSPLANTATION: A MULTINATIONAL DELPHI SURVEY WITH PATIENTS, CAREGIVERS AND HEALTH PROFESSIONALS (2017) (0)
TIME AND DOSE DEPENDENT INCREASE OF IMPDH ACTIVITY AFTER TRANSPLANTATION IN ERYTHROCYTES, BUT NOT IN MONONUCLEAR CELLS (2006) (0)
SP654PREDICTING PATIENT SURVIVAL AT TIME OF KIDNEY TRANSPLANTATION (2016) (0)
FP825IMMUNOLOGIC OUTCOMES IN ELDERLY KIDNEY TRANSPLANT RECIPIENTS (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Klemens Budde?

Klemens Budde is affiliated with the following schools:

Humboldt University of Berlin
Yale University

Klemens Budde's Academic­Influence.com Rankings

Why Is Klemens Budde Influential?

Klemens Budde's Published Works

Published Works

What Schools Are Affiliated With Klemens Budde?

Klemens Budde's AcademicInfluence.com Rankings